Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03315650
Other study ID # RIVA-PCI
Secondary ID
Status Completed
Phase
First received
Last updated
Start date January 1, 2018
Est. completion date June 24, 2021

Study information

Verified date July 2021
Source IHF GmbH - Institut für Herzinfarktforschung
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study evaluates the antithrombotic therapy in patients suffering from atrial fibrillation after stent implantation in Germany. Patients prescribed with the novel oral anticoagulant Rivaroxaban will be followed up over 14 months for their adherence to the medication schedule and for complications that occurred after index PCI.


Description:

Patients suffering from non-valvular atrial fibrillation and presenting with an acute coronary syndrome require special attention with regard to antithrombotic therapy. Current guidelines recommend use of oral anticoagulation for almost all of these patients, the optimal antithrombotic strategy, however, has still to be defined. As with the use of any antithrombotic drug, clinicians need to balance the risks of ischemic stroke and thromboembolism, recurrent cardiac ischemia and/or stent thrombosis, and bleeding and haemorrhagic stroke. A recently published randomized clinical trial (PIONEER AF) compared the combination of a novel oral anticoagulant (NOAC; Rivaroxaban) plus dual anti-platelet therapy (DAPT) with standard therapy consisting of vitamine K inhibitor plus DAPT. Patients treated with Rivaroxaban showed less incidence of bleedings, whereas ischemic complications, death or stroke were equal in the groups compared. The RIVA-PCI Registry aims at providing an overview of the current antithrombotic treatment regimen in Germany in real life. Moreover, for patients receiving Rivaroxaban as part of their medication follow-up data with regard to their adherence to antithrombotic medication as well as complications over an interval of 14 months after index procedure will be evaluated.


Recruitment information / eligibility

Status Completed
Enrollment 1632
Est. completion date June 24, 2021
Est. primary completion date March 31, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Age =18 years and capable of giving written informed consent - Known or newly diagnosed non-valvular atrial fibrillation - PCI with stent implantation during index hospital stay - Written informed consent for participation in observational study (incl. telephone follow-up) - Not simultaneously participating in any randomized trial Exclusion Criteria: - None

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Germany Kerckhoff-Klinik Bad Nauheim
Germany Segeberger Kliniken Bad Segeberg
Germany Gesundheitszentrum Bitterfeld-Wolfen Bitterfeld-Wolfen
Germany Klinikum Links der Weser Bremen
Germany Krankenhaus Buchholz Buchholz
Germany Klinikum Coburg Coburg
Germany SLK-Kliniken Heilbronn Heilbronn
Germany Städtisches Klinikum Ludwigshafen Ludwigshafen
Germany Universitätsklinikum Mannheim Mannheim
Germany Klinikum der Universität München , Campus Großhadern Munich
Germany Kreisklinikum Siegen Siegen
Germany Robert-Bosch-Krankenhaus Stuttgart
Germany Schwarzwald-Baar Klinikum Villingen-Schwenningen

Sponsors (2)

Lead Sponsor Collaborator
IHF GmbH - Institut für Herzinfarktforschung Bayer

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Antithrombotic combination therapies (treatment patterns) in patients with non-valvular AF undergoing PCI Real-life data on the prescription of antithrombotic medication for patients with atrial fibrillation after PCI 18 months
Secondary Evaluation of antithrombotic medication during long-term follow-up Patients receiving Rivaroxaban after index PCI are asked for their further antithrombotic medication in two telephone interviews (3 months and 14 months after index PCI) 14 months
Secondary Adverse Events during baseline and follow-up Documentation of Adverse Events during baseline hospital stay (by treating physician) and during long-term follow-up (patient-reported) 32 months
Secondary Treatment adherence of patients Patient-reported information on their adherence to the antithrombotic treatment strategy 14 months
See also
  Status Clinical Trial Phase
Recruiting NCT06013813 - Conventional vs. Distal Radial Access Outcomes in STEMI Patients Treated by PCI N/A
Recruiting NCT05846893 - Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease N/A
Recruiting NCT05412927 - AngelMed Guardian® System PMA Post Approval Study
Completed NCT02750579 - Early or Delayed Revascularization for Intermediate and High-risk Non ST-elevation Acute Coronary Syndromes? N/A
Completed NCT04102410 - Assessing Force-velocity Profile: an Innovative Approach to Optimize Cardiac Rehabilitation in Coronary Patients N/A
Enrolling by invitation NCT03342131 - Serum Concentration of Wnt2 and Wnt4 in Patients With Acute Coronary Syndrome N/A
Recruiting NCT01218776 - International Survey of Acute Coronary Syndromes in Transitional Countries
Enrolling by invitation NCT04676100 - International CR Registry
Completed NCT03590535 - 5th Generation cTnT in ED ACS
Recruiting NCT05437900 - INSIGHTFUL-FFR Clinical Trial Phase 4
Completed NCT05551429 - Factors Related to Participation in Cardiac Rehabilitation in Patients With Acute Coronary Syndrome
Terminated NCT04316481 - IDE-ALERTS Continued Access Study N/A
Active, not recruiting NCT04475380 - Complex All-comers and Patients With Diabetes or Prediabetes, Treated With Xience Sierra Everolimus-eluting Stents
Not yet recruiting NCT04852146 - Electronic Feedback for Data Restitution and Valorization to the Emergency Teams in Aquitaine.
Active, not recruiting NCT02892903 - In the Management of Coronary Artery Disease, Does Routine Pressure Wire Assessment at the Time of Coronary Angiography Affect Management Strategy, Hospital Costs and Outcomes? N/A
Completed NCT02944123 - Half Dose of Prasugrel and Ticagrelor in Acute Coronary Syndrome (HOPE-TAILOR) Phase 3
Completed NCT04077229 - Piloting Text Messages to Promote Positive Affect and Physical Activity N/A
Not yet recruiting NCT02871622 - BMX Alpha Registry: a Post-market Registry of the BioMatrix Alpha TM N/A
Active, not recruiting NCT02922140 - The Impact of Pharmaceutical Care Practice on Patients in Cardiac Rehabilitation Unit N/A
Completed NCT02673437 - Rivaroxaban ACS Specialist Cohort Event Monitoring Study